<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005198A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005198</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>14012861</doc-number><date>20130828</date></document-id></application-reference><us-application-series-code>14</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>487</main-group><subgroup>04</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>473</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>487</main-group><subgroup>04</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>473</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><classification-national><country>US</country><main-classification>514248</main-classification><further-classification>544280</further-classification><further-classification>5142651</further-classification><further-classification>544277</further-classification><further-classification>51426322</further-classification><further-classification>51426321</further-classification><further-classification>544237</further-classification><further-classification>544262</further-classification><further-classification>5142621</further-classification></classification-national><invention-title id="d0e43">RAF KINASE MODULATORS AND METHODS OF USE</invention-title><us-related-documents><division><relation><parent-doc><document-id><country>US</country><doc-number>12663504</doc-number><date>20100728</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>8557830</doc-number></document-id></parent-grant-document><parent-pct-document><document-id><country>WO</country><doc-number>PCT/US2008/007132</doc-number><date>20080605</date></document-id></parent-pct-document></parent-doc><child-doc><document-id><country>US</country><doc-number>14012861</doc-number></document-id></child-doc></relation></division></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>AMGEN INC.</orgname><address><city>Thousand Oaks</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>SMITH</last-name><first-name>Adrian L.</first-name><address><city>Simi Valley</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>DOHERTY</last-name><first-name>Elizabeth M.</first-name><address><city>Thousand Oaks</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>HUANG</last-name><first-name>Qi</first-name><address><city>Moorpark</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>LIU</last-name><first-name>Gang</first-name><address><city>Oak Park</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>AMGEN INC.</orgname><role>02</role><address><city>Thousand Oaks</city><state>CA</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I</p><p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="40.47mm" wi="58.84mm" file="US20140005198A1-20140102-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0003" num="0000">wherein each of A<sup>1</sup>, A<sup>2</sup>, A<sup>3</sup>, A<sup>4</sup>, A<sup>5</sup>, A<sup>6</sup>, A<sup>7</sup>, A<sup>8</sup>, A<sup>9</sup>, bond B, X, rings Z<sup>1 </sup>and Z<sup>2</sup>, R<sup>1 </sup>and R<sup>3 </sup>are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.</p></abstract></us-patent-application>